Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Manipulation of Regulatory Cells' Responses to Treatments for Chronic Hepatitis B Virus Infection.

Tavakolpour S, Alavian SM, Sali S.

Hepat Mon. 2016 May 25;16(6):e37927. doi: 10.5812/hepatmon.37927. eCollection 2016 Jun.

2.

The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.

Horn L, Reck M, Spigel DR.

Oncologist. 2016 Aug;21(8):910-21. doi: 10.1634/theoncologist.2015-0523. Epub 2016 Jun 27. Review.

PMID:
27354668
3.

PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells.

George AL, Suriano R, Rajoria S, Osso MC, Tuli N, Hanly E, Geliebter J, Arnold AN, Wallack M, Tiwari RK.

J Cancer. 2015 Oct 29;6(12):1320-30. doi: 10.7150/jca.11126. eCollection 2015.

4.

Immune checkpoint inhibitors in NSCLC.

Johnson DB, Rioth MJ, Horn L.

Curr Treat Options Oncol. 2014 Dec;15(4):658-69. doi: 10.1007/s11864-014-0305-5. Review.

5.

What have we learned from cancer immunotherapy in the last 3 years?

Ascierto PA, Marincola FM.

J Transl Med. 2014 May 21;12:141. doi: 10.1186/1479-5876-12-141.

6.

Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation.

Chan DV, Gibson HM, Aufiero BM, Wilson AJ, Hafner MS, Mi QS, Wong HK.

Genes Immun. 2014 Jan;15(1):25-32. doi: 10.1038/gene.2013.57. Epub 2013 Oct 31.

7.

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP.

J Exp Med. 2013 Jul 1;210(7):1389-402. doi: 10.1084/jem.20130066. Epub 2013 Jun 10.

8.

Serum antibodies against CD28-- a new potential marker of dismal prognosis in melanoma patients.

Körner R, Preuss KD, Fadle N, Madjidi D, Neumann F, Bergeler L, Gräber S, Müller CS, Grünhage F, Pfreundschuh M, Lammert F, Vogt T, Pföhler C.

PLoS One. 2013;8(3):e58087. doi: 10.1371/journal.pone.0058087. Epub 2013 Mar 6.

9.

Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor.

Yaddanapudi K, Putty K, Rendon BE, Lamont GJ, Faughn JD, Satoskar A, Lasnik A, Eaton JW, Mitchell RA.

J Immunol. 2013 Mar 15;190(6):2984-93. doi: 10.4049/jimmunol.1201650. Epub 2013 Feb 6.

10.

Melanoma in immunosuppressed patients.

Kubica AW, Brewer JD.

Mayo Clin Proc. 2012 Oct;87(10):991-1003. doi: 10.1016/j.mayocp.2012.04.018. Review.

11.

Biomarkers on melanoma patient T cells associated with ipilimumab treatment.

Wang W, Yu D, Sarnaik AA, Yu B, Hall M, Morelli D, Zhang Y, Zhao X, Weber JS.

J Transl Med. 2012 Jul 12;10:146. doi: 10.1186/1479-5876-10-146.

12.

Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma.

Kleiner DE, Berman D.

Dig Dis Sci. 2012 Aug;57(8):2233-40. doi: 10.1007/s10620-012-2140-5. Epub 2012 Mar 21. No abstract available.

13.

Immunity, cancer and aging: lessons from mouse models.

Myers CE, Mirza NN, Lustgarten J.

Aging Dis. 2011 Dec;2(6):512-23. Epub 2011 Dec 2.

14.

Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.

Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP.

PLoS One. 2011 Apr 29;6(4):e19499. doi: 10.1371/journal.pone.0019499.

15.

Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases.

Manikwar P, Kiptoo P, Badawi AH, Büyüktimkin B, Siahaan TJ.

Med Res Rev. 2012 Jul;32(4):727-64. doi: 10.1002/med.20243. Epub 2011 Mar 23. Review.

16.

Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.

Ginsberg BA, Gallardo HF, Rasalan TS, Adamow M, Mu Z, Tandon S, Bewkes BB, Roman RA, Chapman PB, Schwartz GK, Carvajal RD, Panageas KS, Terzulli SL, Houghton AN, Yuan JD, Wolchok JD.

Clin Cancer Res. 2010 Aug 1;16(15):4057-65. doi: 10.1158/1078-0432.CCR-10-1093. Epub 2010 Jul 20.

17.

B7-H1 expression on old CD8+ T cells negatively regulates the activation of immune responses in aged animals.

Mirza N, Duque MA, Dominguez AL, Schrum AG, Dong H, Lustgarten J.

J Immunol. 2010 May 15;184(10):5466-74. doi: 10.4049/jimmunol.0903561. Epub 2010 Apr 7.

18.

Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.

Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, Xu Y, Li H, Vyas S, Mu Z, Chapman PB, Krown SE, Panageas K, Terzulli SL, Old LJ, Houghton AN, Wolchok JD.

Cancer Immun. 2009 Jun 5;9:5.

Items per page

Supplemental Content

Write to the Help Desk